Raveron® versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Bircan K., ÖZEN H., ERGEN A., Başar I., Özgür S., Ilker Y., ...More

International Urology and Nephrology, vol.22, no.4, pp.345-348, 1990 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 4
  • Publication Date: 1990
  • Doi Number: 10.1007/bf02549794
  • Journal Name: International Urology and Nephrology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.345-348
  • Ankara University Affiliated: No

Abstract

Thirty patients with BPH were randomized into two groups to receive Raveron® and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron® and placebo. © 1990 Akadémiai Kiadó.